Market research
ANIP ANI Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 15.4
- Analyst target
- 105.7778
- Dividend yield
- Not available
- Beta
- 0.49
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- 15.4
- Analyst target
- 105.7778
- Dividend yield
- Not available
- Beta
- 0.49
About
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Research context
ANI Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ANIP discussion.
5 years, 6 months ago
ANI Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
ANI Pharmaceuticals, Inc's total revenue rose by 19.4% to $57M since the same quarter in the previous year.
Its net income has increased by 24.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 328.3% to $-8M since the same quarter in the previous year.
Based on the above factors, ANI Pharmaceuticals, Inc gets an overall score of 4/5.